-
21.发明申请公开(公告)号：US20090162883A1
公开(公告)日：2009-06-25
申请号：US12274115
申请日：2008-11-19
CPC分类号： C07K14/4711 , C12N9/6478 , C12N2799/026 , C12Q1/37 , G01N2333/96472
摘要： The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays. An enzyme that cleaves the α-secretase site of APP also is provided. The invention further provides a modified APP protein and associated nucleic acids, peptides, vectors, cells, and cell isolates, and assays that are particularly useful for identifying candidate therapeutics for treatment or prevention of Alzheimer's disease.
摘要翻译： 本发明提供用于切割APP蛋白和相关核酸，肽，载体，细胞和细胞分离物和测定的β分泌酶切割位点的酶和酶程序。 还提供了切割APP的α-分泌酶位点的酶。 本发明还提供了修饰的APP蛋白和相关核酸，肽，载体，细胞和细胞分离物以及特别可用于鉴定用于治疗或预防阿尔茨海默病的候选治疗剂的测定。
-
公开(公告)号：US07495147B2
公开(公告)日：2009-02-24
申请号：US10107604
申请日：2002-03-26
申请人： Hreinn Stefansson , Valgerdur Steinthorsdottir , Jeffrey R. Gulcher , Mark Gurney , Thorkell Andresson
发明人： Hreinn Stefansson , Valgerdur Steinthorsdottir , Jeffrey R. Gulcher , Mark Gurney , Thorkell Andresson
IPC分类号： G01N33/00 , A01K67/00 , A01K67/027
CPC分类号： C07K14/4756 , A01K67/0276 , A01K2217/05 , A01K2227/105 , A01K2267/0356 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C12Q1/6883 , C12Q2600/156 , G01N33/6893 , G01N2500/04 , G01N2800/2835 , G01N2800/302
摘要： Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the gents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia. Also described are hypomorphic mice for use in identifying phenotypes associated with schizophrenia, as well as for use in assessing agents of interest for neuroleptic activity and for potential therapeutic use for treatment of schizophrenia.
摘要翻译： 公开了包含神经调节蛋白1基因（NRG1）和编码NRG1多肽的核酸。 还描述了编码NRG1多肽的相关核酸; NRG1多肽; 结合NRG1多肽的抗体; 精神分裂症易感性诊断方法; 用于改变NRG1多肽的活性或鉴定NRG1结合剂的试剂的测定法，以及通过测定鉴定的口感或结合剂; NRG1治疗剂，包括NRG1核酸，NRG1多肽或改变NRG1多肽活性的试剂; 包含NRG1治疗剂的药物组合物; 以及精神分裂症治疗方法。 描述了在受影响个体中具有共同核心单体型的新型单元型，以及它们在筛选易感性精神分裂症的方法中的用途。 还描述了用于鉴定与精神分裂症相关的表型的同型小鼠，以及用于评估精神兴奋活性感兴趣的药物和用于治疗精神分裂症的潜在治疗用途。
-
公开(公告)号：US20080263690A1
公开(公告)日：2008-10-23
申请号：US10107604
申请日：2002-03-26
申请人： Hreinn Stefansson , Valgerdur Steinthorsdottir , Jeffrey R. Gulcher , Mark Gurney , Thorkell Andresson
发明人： Hreinn Stefansson , Valgerdur Steinthorsdottir , Jeffrey R. Gulcher , Mark Gurney , Thorkell Andresson
IPC分类号： A01K67/027 , C12Q1/68
CPC分类号： C07K14/4756 , A01K67/0276 , A01K2217/05 , A01K2227/105 , A01K2267/0356 , A61K38/00 , A61K38/179 , C07K14/47 , C07K2319/00 , C12Q1/6883 , C12Q2600/156 , G01N33/6893 , G01N2500/04 , G01N2800/2835 , G01N2800/302
摘要： Nucleic acids comprising the neuregulin 1 gene (NRG1) and encoding NRG1 polypeptides are disclosed. Also described are related nucleic acids encoding NRG1 polypeptides; NRG1 polypeptides; antibodies that bind to NRG1 polypeptides; methods of diagnosis of susceptibility to schizophrenia; assays for agents that alter the activity of NRG1 polypeptide or which identify NRG1 binding agents, and the agents or binding agents identified by the assays; NRG1 therapeutic agents, including the NRG1 nucleic acids, NRG1 polypeptides, or agents that alter the activity of an NRG1 polypeptides; pharmaceutical compositions comprising the NRG1 therapeutic agents; as well as methods of therapy of schizophrenia. Novel haplotypes with a common core haplotype in affected individuals are described, as well as their use in methods for screening for susceptibility to schizophrenia. Also described are hypomorphic mice for use in identifying phenotypes associated with schizophrenia, as well as for use in assessing agents of interest for neuroleptic activity and for potential therapeutic use for treatment of schizophrenia.
摘要翻译： 公开了包含神经调节蛋白1基因（NRG1）和编码NRG1多肽的核酸。 还描述了编码NRG1多肽的相关核酸; NRG1多肽; 结合NRG1多肽的抗体; 精神分裂症易感性诊断方法; 用于改变NRG1多肽的活性或鉴定NRG1结合剂的试剂的测定法和通过测定鉴定的试剂或结合剂; NRG1治疗剂，包括NRG1核酸，NRG1多肽或改变NRG1多肽活性的试剂; 包含NRG1治疗剂的药物组合物; 以及精神分裂症治疗方法。 描述了在受影响个体中具有共同核心单体型的新型单元型，以及它们在筛选易感性精神分裂症的方法中的用途。 还描述了用于鉴定与精神分裂症相关的表型的同型小鼠，以及用于评估精神兴奋活性感兴趣的药物和用于治疗精神分裂症的潜在治疗用途。
-
公开(公告)号：US20050272051A1
公开(公告)日：2005-12-08
申请号：US10944272
申请日：2004-09-17
IPC分类号： A61K31/00 , A61K31/198 , A61K31/381 , A61K31/445 , A61P9/10 , C12Q1/68 , G01N33/50
CPC分类号： A61K31/00 , A61K31/198 , A61K31/381 , A61K31/445 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Linkage of myocardial infarction (MI) with a locus on chromosome 12q23 is disclosed. In particular, the LTA4H gene within this locus is shown by association analysis to be a susceptibility gene for MI. Methods for preventing and/or treating the recurrence of MI, in particular are described.
摘要翻译： 公开了心肌梗塞（MI）与染色体12q23上的位点的连锁。 特别地，通过关联分析将该基因内的LTA4H基因显示为MI的易感基因。 特别是描述了用于预防和/或治疗MI复发的方法。
-
25.发明申请公开(公告)号：US20080090839A1
公开(公告)日：2008-04-17
申请号：US11832816
申请日：2007-08-02
IPC分类号： A61K31/495 , A61K31/40 , A61P29/00 , C07D211/22 , C07D295/033 , C07D207/06 , A61K31/4453
CPC分类号： C07D207/08 , C07D295/088 , C07D295/15
摘要： A chemical genus of biphenyl heterocycle derivative inhibitors of LTA4H (leukotriene A4 hydrolase) of the formula: is disclosed. In these compounds Q and Z are (CH2)1-10; in which one or two (CH2) may optionally be replaced by —O—, —NR1—, —SO—, —S(O)2—, —C(═O)— or —C═O(NH)—; Het is a 5-7 membered non-aromatic nitrogen heterocycle; and W is acyl, hydroxyl, carboxyl, amino, carboxamido, aminoacyl, —COOalkyl, —CHO, heterocyclyl, substituted aryl, or substituted heterocyclyl, or taken together ZW can be H or —COOalkyl. The compounds are useful for the treatment and prevention and prophylaxis of inflammatory diseases and disorders.
摘要翻译： 公开了具有下式的LTA4H（白三烯A4水解酶）的联苯基杂环衍生物抑制剂的化学属。 在这些化合物中，Q和Z是（CH 2）2 - 其中一个或两个（CH 2）2可以任选地被-O-，-NR 1 - ， - SO - ， - S（O）2 -C（ - ） - 或-CO（NH） - ; Het是5-7元非芳族氮杂环; 并且W是酰基，羟基，羧基，氨基，甲酰氨基，氨酰基，-COO烷基，-CHO，杂环基，取代的芳基或取代的杂环基，或一起ZW可以是H或-COO烷基。 该化合物可用于治疗和预防和预防炎性疾病和病症。
-
26.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment 失效心肌梗塞，中风和PAOD的易感基因; 治疗方法公开(公告)号：US20070280917A1
公开(公告)日：2007-12-06
申请号：US11270804
申请日：2005-11-09
CPC分类号： C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： Polymorphisms in the FLAP and LTA4H gene are shown by genetic association analysis to be susceptibility markers for myocardial infarction (MI) and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides methods of prophylaxis therapy for MI in human subjects having a race including black African ancestry by administering to the subject a composition comprising a therapeutically effective amount of MI therapeutic agent that inhibits leukotriene synthesis in vivo. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a statin and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
摘要翻译： FLAP和LTA4H基因的多态性通过遗传关联分析显示为心肌梗死（MI）和ACS以及中风和PAOD的敏感性标志物。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供了通过向受试者施用包含治疗有效量的体内抑制白细胞三烯合成的MI治疗剂的组合物的组合，在具有包括黑非洲血统的种族的人类受试者中预防MI治疗的方法。 本发明还提供了包含白三烯合成抑制剂和他汀类的组合物以及使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者中的C-反应蛋白的方法。
-
公开(公告)号：US20060029546A1
公开(公告)日：2006-02-09
申请号：US10912971
申请日：2004-08-06
CPC分类号： A61K49/0008 , G01N33/6896 , G01N2333/70571 , G01N2800/302 , G01N2800/52
摘要： The invention relates to materials and methods of identifying modulators of N-methyl-D-Aspartate (NMDA) receptor phosphorylation and function, including anti-schizophrenic agents that modulate NMDA receptor function. The methods of the invention utilize animal models of schizophrenia and cell-based assays to identify modulators of NMDA function. The invention further provides anti-schizophrenic agents identified by these methods. The invention relates to methods of treating schizophrenia using the modulators and anti-schizophrenic agents identified by the methods of the invention.
摘要翻译： 本发明涉及鉴定N-甲基-D-天门冬氨酸（NMDA）受体磷酸化和功能的调节剂的材料和方法，包括调节NMDA受体功能的抗精神分裂剂。 本发明的方法利用精神分裂症的动物模型和基于细胞的测定来鉴定NMDA功能的调节剂。 本发明还提供了通过这些方法鉴定的抗精神分裂药物。 本发明涉及使用通过本发明的方法鉴定的调节剂和抗精神分裂症药物治疗精神分裂症的方法。
-
公开(公告)号：US20050095671A1
公开(公告)日：2005-05-05
申请号：US10653676
申请日：2003-09-02
申请人： Mark Gurney , Adele Pauley , Jinhe Li
发明人： Mark Gurney , Adele Pauley , Jinhe Li
IPC分类号： C12N15/09 , C07K14/47 , C07K16/18 , C12N5/02 , C12N5/10 , C12N15/12 , C12Q1/68 , C07H21/04 , C07K14/705
CPC分类号： C07K14/4702 , C07K2319/00
摘要： The present invention provides isolated nucleic acid molecules comprising a polynucleotide encoding either of two alternative splice variants of human sel-10, one of which is expressed in hippocampal cells, and one of which is expressed in mammary cells. The invention also provides isolated sel-10 polypeptides and cell lines which express them in which Aβ processing is altered.
摘要翻译： 本发明提供了分离的核酸分子，其包含编码人sel-10的两个可变剪接变体之一的多核苷酸，其中一个在海马细胞中表达，其中一个在乳腺细胞中表达。 本发明还提供分离的sel-10多肽和表达它们的细胞系，其中Abeta处理被改变。
-
公开(公告)号：US20050026256A1
公开(公告)日：2005-02-03
申请号：US10940867
申请日：2004-09-14
申请人： Mark Gurney , Michael Bienkowski , Robert Heinrikson , Luis Parodi , Riqiang Yan
发明人： Mark Gurney , Michael Bienkowski , Robert Heinrikson , Luis Parodi , Riqiang Yan
IPC分类号： G01N33/50 , A61K38/48 , A61K45/00 , A61P25/28 , C07K20060101 , C07K5/00 , C07K14/00 , C07K14/435 , C07K14/47 , C07K16/18 , C07K19/00 , C12N20060101 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/00 , C12N5/06 , C12N5/10 , C12N5/16 , C12N9/50 , C12N9/64 , C12N9/82 , C12N15/09 , C12N15/12 , C12N15/57 , C12N15/62 , C12N15/63 , C12N15/79 , C12N15/85 , C12N15/86 , C12P21/00 , C12P21/02 , C12P21/08 , C12Q20060101 , C12Q1/37 , C12R1/19 , G01N20060101 , G01N33/15 , G01N33/68 , C12Q1/68 , C07H21/04 , C07K14/705
CPC分类号： C12N9/6478 , C07K14/4711 , C07K2319/00 , C12N2799/026 , C12Q1/37 , G01N2333/96472
摘要： The present invention provides the enzyme and enzymatic procedures for cleaving the β secretase cleavage site of the APP protein and associated nucleic acids, peptides, vectors, cells and cell isolates and assays.
摘要翻译： 本发明提供用于切割APP蛋白和相关核酸，肽，载体，细胞和细胞分离物和测定的β分泌酶切割位点的酶和酶程序。
-
30.发明申请Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment 审中-公开心肌梗塞，中风和PAOD的易感基因，治疗方法公开(公告)号：US20060019269A1
公开(公告)日：2006-01-26
申请号：US11096191
申请日：2005-03-30
IPC分类号： C12Q1/68 , A61K31/401 , A61K31/366 , A61K31/225
CPC分类号： A61K31/225 , A61K31/366 , A61K31/401 , A61K38/00 , C07K14/4705 , C12Q1/6883 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N2800/324
摘要： Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.
摘要翻译： 公开了心肌梗塞（MI）和染色体13q12上的位点的连锁。 特别地，通过遗传关联分析将该基因内的FLAP基因显示为MI和ACS以及中风和PAOD的易感基因。 描述了针对治疗和诊断应用的途径，用于鉴定那些处于发展中心，ACS，中风或PAOD风险的患者。 本发明还提供包含白三烯合成抑制剂的组合物和使用这些组合物降低患有MI，ACS，中风和/或PAOD风险的人类受试者的C-反应蛋白的说明和方法。
-
-
-
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.049 秒)
